COVID-19 Vaccine During Pregnancy Linked to Lower Preeclampsia Risk – Study

New research offers encouraging evidence that COVID-19 vaccination during pregnancy, especially when a booster dose is included, is linked to a significantly reduced risk of preeclampsia, a serious blood pressure disorder that can develop during pregnancy. The findings, stemming from a large multinational study, also suggest potential benefits in lowering the risk of preterm birth and improving overall maternal and infant health outcomes. This builds on growing understanding of the protective effects of vaccination extending beyond direct COVID-19 infection prevention.

Understanding Preeclampsia and Its Impact

Preeclampsia is a condition characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. It affects up to 8% of pregnancies globally and remains a leading cause of maternal and neonatal illness and death, particularly in settings with limited access to healthcare. Researchers have linked the condition to abnormal placental development, systemic inflammation, and endothelial dysfunction – processes that also appear to be implicated in severe COVID-19. This overlap sparked interest in whether vaccination could influence these pathways and potentially offer protection.

The INTERCOVID Consortium Study: A Broad View

The study, published in eClinicalMedicine, analyzed data from 6,527 pregnant women across 18 countries, enrolled between 2020 and 2022. Investigators from the ‘Ann & Robert H. Lurie’ Children’s Hospital of Chicago and the University of Oxford led the research, comparing vaccinated and unvaccinated women, and those with and without SARS-CoV-2 infection. The goal was to determine if vaccination status independently influenced preeclampsia rates. The large scale and geographical diversity of the study – incorporating data from over 40 hospitals – provides a robust view of the relationship between vaccination, infection, and pregnancy outcomes.

Key Findings: Vaccination and Reduced Risk

The analysis revealed a concerning link between COVID-19 infection during pregnancy and an increased risk of preeclampsia: a 45% increase rising to 78% among unvaccinated women. However, vaccination offered a significant degree of protection. Vaccination with a booster dose was associated with a 33% reduction in the risk of preeclampsia, a statistically significant finding. This protective effect appeared particularly strong for women with pre-existing health conditions like diabetes, hypertension, or thyroid disorders, where a booster dose cut preeclampsia risk by 42%, also statistically significant.

Beyond preeclampsia, vaccinated women also experienced lower rates of preterm delivery, maternal morbidity and mortality, and severe perinatal morbidity and mortality. Specifically, a booster dose correlated with a 33% reduction in preterm birth, a 32% reduction in maternal morbidity and mortality, and a 29% reduction in severe perinatal morbidity and mortality.

What Does This Mean for Pregnant Individuals?

These findings reinforce the importance of COVID-19 vaccination during pregnancy, including staying up-to-date with booster doses. Dr. Jagjit S. Teji, a neonatologist at Lurie Children’s, emphasized that the study offers “evidence from the first large study suggesting that COVID vaccination may protect against one of the most serious pregnancy complications.” The University of Oxford news release highlights that the benefits appear independent of whether or not a woman contracts COVID-19, suggesting a broader immunological or vascular benefit from vaccination.

It’s crucial to note that this study is observational, meaning it can demonstrate an association but cannot definitively prove that vaccination *causes* the reduction in preeclampsia risk. Residual confounding – the possibility that other factors not fully accounted for could be influencing the results – remains possible, despite the researchers’ efforts to adjust for known risk factors. However, the study’s size and international scope strengthen the confidence in its findings.

Beyond COVID-19: Exploring ‘Non-Specific’ Vaccine Effects

The researchers suggest that COVID-19 vaccination may modulate immune and vascular pathways that contribute to preeclampsia, potentially offering benefits even in the absence of documented infection. This aligns with growing discussion around “non-specific” vaccine effects – immune-modulatory benefits that extend beyond protection against the targeted pathogen. Dr. José Villar, senior co-author of the study, explained that the results suggest vaccination may influence the pathways involved in preeclampsia development.

Public Health Implications and Next Steps

The INTERCOVID Consortium’s findings support integrating COVID-19 vaccination, including booster doses, into routine antenatal care and prioritizing equitable access for pregnant people globally. Public health officials will likely consider these findings as they refine vaccination recommendations and strategies. Further research is needed to fully understand the mechanisms by which vaccination may protect against preeclampsia and to determine the optimal vaccination schedule during pregnancy. Ongoing surveillance of pregnancy outcomes and vaccination rates will be crucial to monitor the long-term impact of these findings and to identify any emerging trends.

Pregnant individuals should discuss COVID-19 vaccination with their healthcare provider to make informed decisions based on their individual risk factors and circumstances. Staying informed about the latest public health guidance from organizations like the CDC and WHO is also recommended.